Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(32 sites)

China

Research Site, Beijing

Research Site, Changsha

Research Site, Chengdu

Research Site, Fuzhou

Research Site, Guangzhou

Research Site, Hangzhou

Research Site, Harbin

Research Site, Jinan

Research Site, Nanjing

Research Site, Ningbo

Research Site, Shanghai

Research Site, Shenyang

Research Site, Tianjin

Research Site, Wenzhou

Research Site, Wuhan

Research Site, Xi'an

Research Site, Zhangjiagang

Research Site, Zhengzhou